Skip to main content
Clinical Trials/NCT00793559
NCT00793559
Unknown
Phase 2

Terlipressin Administration in Septic Shock Refractory to Catecholamines Bolus vs. Continuous Drip-Phase II

Assaf-Harofeh Medical Center1 site in 1 country30 target enrollmentNovember 2008
ConditionsSeptic Shock
Interventionsterlipressin

Overview

Phase
Phase 2
Intervention
terlipressin
Conditions
Septic Shock
Sponsor
Assaf-Harofeh Medical Center
Enrollment
30
Locations
1
Primary Endpoint
CI, SVR,HR,BP, noradrenalin administration,renal function
Last Updated
17 years ago

Overview

Brief Summary

terlipressin is given to refractory septic shock patients who do not respond to noradrenalin in Israel and Europe. It is given by bolus injection. we attempt to investigate weather it is better to give it by continuous drip and avoid abrupt changes in BP and heart function

Registry
clinicaltrials.gov
Start Date
November 2008
End Date
July 2009
Last Updated
17 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • septic shock patients receiving above 0.5 mcg/kg NA

Exclusion Criteria

  • allergy to terlipressin, CHF, IHD, pregnancy

Arms & Interventions

terlipressin bolus

1 mg of terlipressin received one time only

Intervention: terlipressin

terlipressin drip

Intervention: terlipressin

Outcomes

Primary Outcomes

CI, SVR,HR,BP, noradrenalin administration,renal function

Time Frame: 6 mo

Study Sites (1)

Loading locations...

Similar Trials